About Dualitas Therapeutics
Pioneering the Future of Bispecific Antibody Therapies
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Founded
- 2023
- Company type
- Privately Held
Dualitas Therapeutics is a biotechnology company pioneering the future of bispecific antibody therapies for immune and inflammatory (I&I) diseases and beyond. Powered by our proprietary DualScreen™ discovery engine and a growing library of novel cell surface proximity engagers, our pipeline - including lead programs DTX-103 and DTX-102 - has demonstrated compelling preclinical evidence supporting its potential to address important unmet patient needs. We offer partnering opportunities on the next generation of bispecific therapies in I&I diseases – and beyond.
Notice on Fraudulent Job Offers and Recruiting Activities: Dualitas Therapeutics has been made aware of fraudulent recruiting activity in which individuals falsely claim to represent our company. These scammers may offer fake job opportunities and attempt to collect personal or financial information. All legitimate communication from Dualitas comes from email addresses ending in @dualitastx.com Our only official website is www.dualitastx.com, and our official LinkedIn page is linkedin.com/company/dualitas-therapeutics. Any other domains, pages, or variations should be considered suspicious. Dualitas does not conduct interviews through text or messaging apps, does not ask candidates to download software, does not request payments or financial information, and does not issue job offers without in‑person interviews.
On LinkedIn
- People linked to this company
- 21
People who list this company on LinkedIn, not a verified employee count. Figures reflect the saved company profile.
Explore the company
Employer category
Other employer
Estimated from the company profile. This category has not been confirmed by the employer.